BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 38486335)

  • 1. Establishment of glioma prognosis nomogram based on the function of meox1 in promoting the progression of cancer.
    Pan P; Guo A; Peng L
    Heliyon; 2024 May; 10(9):e29827. PubMed ID: 38707372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unraveling the molecular mechanisms of lymph node metastasis in ovarian cancer: focus on MEOX1.
    Li J; Sun Y; Zhi X; Sun Y; Abudousalamu Z; Lin Q; Li B; Yao L; Chen M
    J Ovarian Res; 2024 Mar; 17(1):61. PubMed ID: 38486335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
    Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
    J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cysteine-Rich Intestinal Protein 1 Served as an Epithelial Ovarian Cancer Marker via Promoting Wnt/
    Liu Y; Li W; Luo J; Wu Y; Xu Y; Chen T; Zhang W; Fu F
    Dis Markers; 2021; 2021():3566749. PubMed ID: 34413913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
    Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
    J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic miR-532-5p-correlated ceRNA-mediated lipid droplet accumulation drives nodal metastasis of cervical cancer.
    Shang C; Li Y; He T; Liao Y; Du Q; Wang P; Qiao J; Guo H
    J Adv Res; 2022 Mar; 37():169-184. PubMed ID: 35499057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follistatin-Like 3 Correlates With Lymph Node Metastasis and Serves as a Biomarker of Extracellular Matrix Remodeling in Colorectal Cancer.
    Yang C; Cao F; Huang S; Zheng Y
    Front Immunol; 2021; 12():717505. PubMed ID: 34335633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
    Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
    Front Immunol; 2022; 13():943389. PubMed ID: 36003381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphatic vessels in cancer.
    Dieterich LC; Tacconi C; Ducoli L; Detmar M
    Physiol Rev; 2022 Oct; 102(4):1837-1879. PubMed ID: 35771983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer statistics, 2022.
    Siegel RL; Miller KD; Fuchs HE; Jemal A
    CA Cancer J Clin; 2022 Jan; 72(1):7-33. PubMed ID: 35020204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MEOX1 suppresses the progression of lung cancer cells by inhibiting the cell-cycle checkpoint gene CCNB1.
    Xiao X; Rui B; Rui H; Ju M; Hongtao L
    Environ Toxicol; 2022 Mar; 37(3):504-513. PubMed ID: 34837450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of epithelial ovarian cancer.
    Kuroki L; Guntupalli SR
    BMJ; 2020 Nov; 371():m3773. PubMed ID: 33168565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcription factors in epithelial ovarian cancer: histotype-specific drivers and novel therapeutic targets.
    Nameki R; Chang H; Reddy J; Corona RI; Lawrenson K
    Pharmacol Ther; 2021 Apr; 220():107722. PubMed ID: 33137377
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.